title: Treating Schizophrenia With the Diuretic Bumetanide: A Case Report.
abstract: Administration of the diuretic and NKCC1 chloride cotransporter antagonist bumetanide reduces the severity of autism spectrum disorders in children, and this effect is mediated by a reduction of the elevated intracellular chloride concentrations and a reinforcement of GABAergic inhibition (Lemonnier et al Transl Psychiatry. 2012;2:e202; Tyzio et al Science. 2014;343:675-679). Here, we report that this treatment also reduces the severity of symptoms in an adolescent with schizophrenia. Long-term treatment reduced hallucinations significantly, suggesting that this treatment may also be useful to treat schizophrenia. Further clinical trials and experimental studies are warranted to test this hypothesis.
authors.affiliation: *Centre Expert Autisme Limousin, Limoges; and †Neurochlore c/o Inmed, INSERM U901, Marseilles, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Lemonnier
authors.forename: Alain
authors.initials: A
authors.lastname: Lazartigues
authors.forename: Yehezkel
authors.initials: Y
authors.lastname: Ben-Ari
mesh_terms: D002034:Bumetanide / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use*; D006801:Humans; D007398:Interpersonal Relations; D008297:Male; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D055815:Young Adult
chemical_list: D004232:Diuretics; D002034:Bumetanide